SPECIAL FEATURES

CCR Translations

6083
Real-time Pathology to Guide Breast Surgery: Seeing Alone Is Not Believing
Irving J. Bigio
See article p. 6315

6086
Regulatory T Cells Move in When Gliomas Say "I DO"
Bryan D. Choi, Peter E. Fecci, and John H. Sampson
See article p. 6110

Molecular Pathways

6089
Molecular Pathways: The Metabolic Regulator Estrogen-Related Receptor α as a Therapeutic Target in Cancer
Ching-yi Chang and Donald P. McDonnell

6096
Molecular Pathways: Regulation of Metabolism by RB
Brian F. Clem and Jason Chesney

Review

6101
Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop

6108
Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

Expression Profiling of Archival Tumors for Long-term Health Studies
Levi Waldron, Shuji Ogino, Yujin Hoshida, Koarishi Shima, Amy E. McCrart Reed, Peter T. Simpson, Yoshifumi Baba, Katsuhiko Nosho, Nicola Segata, Ana Cristina Vargas, Margaret C. Cummings, Sunil R. Lakhani, Gregory J. Kirkner, Edward Giovannucci, John Quackenbush, Todd R. Golub, Charles S. Fuchs, Giovanni Parmigiani, and Curtis Huttenhower

Decreased NK Cells in Patients with Head and Neck Cancer Determined in Archival DNA

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Kelly Boucher, Nancy Parquet, Raymond Widen, Kenneth Shain, Rachid Baz, Melissa Alsina, John Koomen, Claudio Anasetti, William Dalton, and Lia E. Perez

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan, Ronglai Shen, Daphne C. Ang, Melissa L. Johnson, Sandra P. D’Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Biely, Mark G. Kris, Maureen F. Zakowski, and Marc Ladanayi

Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma
Yoko Takahashi, Michael E. Kupferman, Diana Bell, Tilahun Jiffar, June Goo Lee, Tong-Xin Xie, Ning-Wei Li, Mei Zhao, Mitchell J. Frederick, Alexander Gelbard, Jeffrey N. Myers, and Ehab Y. Hanna
Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis

Proliferation in the Normal FTE Is a Hallmark of the Follicular Phase, Not BRCA Mutation Status
Sophia H.L. George, Anca Milea, and Patricia A. Shaw

Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies
Eliane Fischer, Krishna Chaitanya, Thomas Wiester, Andreas Wadle, Andrew M. Scott, Maries van den Broek, Roger Schibli, Stefan Bauer, and Christoph Renner

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
Junako Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakao, Koarou Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takeawa, Kiyoko Kuwata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, and Kazuhiiko Nakagawa

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vv9Vv2 T-Cell Antitumor Cytotoxicity through ICAM-1 Engagement
Ismahéen Benzaid, Hannu Mönkkönen, Edith Bonneyle, Jukka Mönkkönen, and Philippe Clézardin

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
Maria T. Di Martino, Emanuela Leone, Nicola Amadio, Umberto Foresta, Marta Lionetti, Maria R. Pitarri, Maria E. Gallo Cantafio, Annamaria Guilla, Francesco Conforti, Eugenio Morelli, Vera Tomain, Marco Rossi, Massimo Negri, Manlio Ferrarini, Michele Caraglia, Massoud A. Shammas, Nikhil C. Munsbi, Kenneth C. Anderson, Antonino Neri, Pierosandro Tagliaferri, and Pierfrancesco Tassone

TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-1/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles
Taeko Matsushima-Miyagi, Koji Hatano, Motonari Nomura, Liu Li-Wen, Tomoyuki Nishikawa, Kotaro Saga, Takashi Shimbo, and Yasufumi Kaneda

Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Magalie Dosset, Yann Godet, Charline Vauchy, Laurent Beziard, Yu Chun Lone, Christine Sedliik, Christelle Liard, Emeline Levionnois, Bertrand Clerc, Federico Sandoval, Etienne Daguidanau, Simon Wain-Hobson, Eric Tartour, Pierre Langlade-Demoyen, Christophe Borg, and Olivier Adotevi

Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands
Wing Keung Chan, May Kung Sutherland, Ying Li, Jonathan Zalevsky, Sarah Schell, and Wing Leung
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Sections</th>
</tr>
</thead>
<tbody>
<tr>
<td>6306</td>
<td>Measurement of Tumor VEGF-A Levels with $^{89}$Zr-Bevacizumab PET as an Early Biomarker for</td>
<td>Arne R.M. van der Bilt, Anton G.T. Terwisscha van Scheltinga, Hetty</td>
<td>CANCER THERAPY: CLINICAL</td>
</tr>
<tr>
<td></td>
<td>the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model</td>
<td>Timmer-Bosscha, Carolien P. Schröder, Linda Pot, Jos G.W. Kosterink,</td>
<td>Outcomes of Phase II Clinical Trials with Single-Agent Therapies in</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ate G.J. van der Zee, Marjolijn N. Lub-de Hooge, Steven de Jong, Elies</td>
<td>Advanced/Metastatic Non–Small Cell Lung Cancer Published between</td>
</tr>
<tr>
<td></td>
<td></td>
<td>beth G.E. de Vries, and Anna K.L. Reyners</td>
<td>2000 and 2009</td>
</tr>
<tr>
<td>6315</td>
<td>Scatter Spectroscopic Imaging Distinguishes between Breast Pathologies in Tissues Relevant</td>
<td>Ashley M. Laughney, Venkataramanan Krishnaswamy, Elizabeth J. Rizzo,</td>
<td>Using Pharmacokinetic and Pharmacodynamic Data in Early Decision</td>
</tr>
<tr>
<td></td>
<td>to Surgical Margin Assessment</td>
<td>Richard J. Barth, Brian W. Pogue, Keith D. A. Paulsen, and Wendy A.</td>
<td>Making Regarding Drug Development: A Phase I Clinical Trial Evaluating</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wells</td>
<td>Tyrosine Kinase Inhibitor, AEE788</td>
</tr>
<tr>
<td>6326</td>
<td>Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior</td>
<td>Shunsuke Kondo, Satoshi Iwata, Takeko Yamada, Yusuke Inoue, Hiromi</td>
<td>Personalized Medicine in a Phase I Clinical Trials Program: The MD</td>
</tr>
<tr>
<td></td>
<td>of Human Lung Cancer</td>
<td>Ichihara, Yoshiko Kichikawa, Tomoki Katayose, Akiko Souta-Kuribara,</td>
<td>Anderson Cancer Center Initiative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hiroto Yamazaki, Osamu Hosono, Hiroshi Kawasaki, Hiroshi Tanaka,</td>
<td>Apostolos-Maria Tsimeridou, Nancy G. Iskander, David S. Hong, Jennifer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yuichiro Hayashi, Michiie Sakamoto, Kazunori Kamiya, Nam H. Dang, and</td>
<td>Wheler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chikao Morimoto</td>
<td>Filip Janku, Rajyalakshmi Luthra, Yang Ye, Sijin Wen, Donald Berry,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>and Razelle Kurzrock</td>
</tr>
<tr>
<td>6339</td>
<td>Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for</td>
<td>Shinich Yachida, Catherine M. White, Yoshiki Naito, Yi Zhong, Jacqueline</td>
<td>Association between VEGF Splice Isoforms and Progression-Free</td>
</tr>
<tr>
<td></td>
<td>Identification of Potential Long-term Survivors</td>
<td>A. Brosnan, Anne M. Macgregor-Das, Richard A. Morgan, Tyler Saunders,</td>
<td>Survival in Metastatic Colorectal Cancer Patients Treated with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daniel A. Laheru, Joseph M. Herman, Ralph H. Hruban, Alison P. Klein,</td>
<td>Bevacizumab</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sián Jones, Víctor Velculescu, Christopher L. Wolfgang, and Christine</td>
<td>David O. Bates, Paul J. Catalano, Kirsty E. Symonds, Alex H.R. Varey,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Iacobuzu-Donahue</td>
<td>Pramila Ramani, Peter J. O'Dwyer, Bruce J. Giontonio, Neal J. Meropol,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Al Bowen Benson, and Steven J. Harper</td>
</tr>
<tr>
<td>6348</td>
<td>Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases</td>
<td>Janet E. Brown, Richard J. Cook, Allan Lipton, and Robert E. Coleman</td>
<td></td>
</tr>
<tr>
<td></td>
<td>from Breast Cancer: A Retrospective Analysis in Biphosphonate-Treated Patients</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Replication-incompetent Sendai virus particles were injected into orthotopic prostate cancers in NOD-SCID mice on day 29 after the inoculation of human prostate cancer PC3 cells. The dual 4',6-diamidino-2-phenylindole (blue) and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (DAPI; green) staining showed that the TUNEL-positive apoptotic cells were dramatically increased in tumor regions. For details, see the article by Matsushima-Miyagi and colleagues on page 6271 of this issue.
## Clinical Cancer Research

**18 (22)**

*Clin Cancer Res* 2012;18:6081-6391.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/18/22">http://clincancerres.aacrjournals.org/content/18/22</a></th>
</tr>
</thead>
</table>

### E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

### Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

### Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.